GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy

Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Young Eun, Usnich, Tatiana, Scherzer, Clemens R., Klein, Christine, Chung, Sun Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Movement Disorder Society 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548077/
https://www.ncbi.nlm.nih.gov/pubmed/37302978
http://dx.doi.org/10.14802/jmd.23023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548077/
https://www.ncbi.nlm.nih.gov/pubmed/37302978
http://dx.doi.org/10.14802/jmd.23023

Ejemplares similares